Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)Seeking Alpha • 03/15/23
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart DiseasePRNewsWire • 03/15/23
Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare ConferenceSeeking Alpha • 03/13/23
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA reviewGlobeNewsWire • 03/07/23
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA ReviewGlobeNewsWire • 03/07/23
Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript)Seeking Alpha • 03/06/23
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia RheumaticaGlobeNewsWire • 03/01/23
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)GlobeNewsWire • 02/24/23
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority ReviewGlobeNewsWire • 02/21/23
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)Seeking Alpha • 02/14/23
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDAGlobeNewsWire • 02/08/23
Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart PatternInvestors Business Daily • 02/03/23